Tsoukka M, Jelastopulu E, Lavranos G, Charalambous G. Estimation of quality of life in Cypriot patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(1): 121-126 [PMID: 28104987 DOI: 10.3748/wjg.v23.i1.121]
Corresponding Author of This Article
Maria Tsoukka, PhD candidate, MSc Health Management, Postgraduate Program Health Management, Frederick University, Nicosia, Cyprus University General Hospital of Larnaca, Kalavardon No. 16, Dromolaxia, Larnaca 7020, Cyprus. mariate@windowslive.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 7, 2017; 23(1): 121-126 Published online Jan 7, 2017. doi: 10.3748/wjg.v23.i1.121
Table 1 Demographic and disease characteristics of the study population n (%)
Total
CD
UC
P value
n = 100
n = 40
n = 60
Sex
0.198
Male
54 (53.5)
61.5%
48.3%
Female
46 (46.5)
38.5%
51.7%
Age (yr) (n = 97)
n = 38
n = 59
18-35
39 (39.8)
16 (41.0)
23 (39.0)
0.979
35-50
28 (28.6)
11 (28.2)
17 (28.8)
> 51
30 (31.6)
11 (30.8)
19 (32.2)
Smoking
32 (33.0)
43.2%
26.7%
0.092
Education
0.673
Primary or less
17.3%
18.4%
16.7%
Secondary
49.0%
42.1%
53.3%
Tertiary or above
33.7%
39.5%
30.0%
Employment status
0.349
Government officials
19.8%
22.9%
18.3%
Private employee
44.8%
44.4%
45.0%
Self–employed
4.2%
8.3%
1.7%
Unemployed
31.3%
25.0%
35.0%
Family status
0.822
Married
62.6%
59.0%
65.0%
Unmarried
32.3%
35.9%
30.0%
Divorced
5.1%
5.1%
5.0%
Surgery
20.9%
36.1%
11.7%
0.004
Mean disease duration (yr)
12.63%
10.28%
14.07%
0.118
Treatment
0.019
Immunosuppressive treatment
65.0%
55.0%
71.7%
Immunosuppressive treatment + corticosteroids
16.0%
12.5%
18.3%
Treatment with biologic agents
19.0%
32.5%
10.0%
Treatment with corticosteroids
22.0%
17.5%
25.0%
0.375%
Table 2 Short inflammatory bowel disease questionnaire score by dimension and type of disease (n = 100), mean (± SD) n (%)
Crohn’s disease
Ulcerative colitis
Physical dimension
18.53 (7.55)
19.52 (6.74)
Psychological dimension
10.68 (5.31)
11.88 (4.49)
Social dimension
7.92 (3.03)
8.63 (3.18)
Overall SIBDQ
33.79 (13.36)
36.30 (11.39)
Table 3 Physical Dimension scores of health-related quality of life in patients with Crohn’s disease and ulcerative colitis and their association to demographic parameters
Physical dimension
Crohn’s disease, median
Ulcerative colitis, median
Gender
Male
3.3
4.2
Female
3.5
3.4
Z
-0.015
-2.274
P value
0.988
0.023
Age
< 35
3.1
4.0
35-50
3.8
3.2
> 50
3.8
4.2
χ2
1.232
7.767
P value
0.540
0.021
Table 4 Psychological dimension scores of health-related quality of life in patients with Crohn’s disease and ulcerative colitis and their association to demographic parameters
Psychological dimension
Crohn’s disease, median
Ulcerative colitis, median
Gender
Male
3.17
5.00
Female
2.83
3.00
Z
-0.456
-3.474
P value
0.648
0.001
Age
< 35
2.83
4.00
35-50
2.33
2.67
> 51
4.67
4.67
χ2
1.011
5.979
P value
0.603
0.0503
Family status
Married
3.83
4.00
Single
2.33
3.50
Z
6.351
-0.663
P value
0.042
0.507
Table 5 Scores of health-related quality of life in patients with Crohn’s disease and ulcerative colitis in association to medication treatment
Medication
Median
Z
P value
Physical dimension
Biological factors
5.00
-1.484
0.138
Standard treatment
3.20
Psychological dimension
Biological factors
4.67
-1.584
0.113
Standard treatment
2.67
Social dimension
Biological factors
5.00
-2.004
0.045
Standard treatment
3.25
Citation: Tsoukka M, Jelastopulu E, Lavranos G, Charalambous G. Estimation of quality of life in Cypriot patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(1): 121-126